GSK has announced an investment of $30bn in the US over the next five years for research and development (R&D) and supply chain infrastructure.
The investment includes a $1.2bn package for advanced manufacturing, AI and digital technologies.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GSK said the package will support new biopharma factories and laboratories.
The announcement comes after US President Donald Trump visited Britain to seal investment deals, reported Reuters.
GSK CEO Emma Walmsley said: “Alongside the many longstanding and vital shared interests that connect the UK and the US is advancing life sciences to get ahead of disease.
“This week’s State Visit brings together two countries that have led the world in science and healthcare innovation. We are proud to be part of both.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Here in the UK, we continue to invest in a significant manufacturing base and more than £1.5bn in R&D every year.”
The $1.2bn allocation will finance a biologics flex factory at Upper Merion in Pennsylvania, with construction due to start in 2026, and will deliver new medicines for respiratory diseases and cancer.
It will also support new drug substance manufacturing capability and enhanced device and auto injector assembly.
GSK will also deploy AI and advanced digital tools across five manufacturing sites in Pennsylvania, North Carolina, Maryland and Montana.
The measures are expected to create hundreds of skilled US jobs in addition to construction roles.
The company said the total investment covers capital spending across its US supply chain and funding for drug discovery, development and clinical trials.
In the previous year, the drugmaker committed $2bn to US manufacturing, including an $800m facility, which is under construction at its site in Marietta, Pennsylvania.
Last month, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted approval to GSK’s oral antibiotic pill, Blujepa (gepotidacin), for uncomplicated urinary tract infections (UTIs) in females aged 12 years and above.
